NLRP6 and metabolic dysfunction-associated steatohepatitis: In NASH mouse models, Huang et al. found that NLRP6 accelerates the degradation of TGF-β activated kinase 1 binding protein 2/3 (TAB2/3) through a lysosomal dependent pathway, thereby suppressing NF-κB mediated inflammatory responses (70).